科伦博泰生物宣布，其靶向Trop2的抗体药物偶联物（ADC）Sacituzumab Tirumotecan联合帕博利珠单抗（Pembrolizumab）的三期临床研究已达到主要终点。
该研究旨在评估联合疗法在特定适应症中的疗效与安全性。主要终点的达成，标志着该治疗方案在关键临床试验中取得了积极结果，为后续的注册申请奠定了重要基础。
此次成功是科伦博泰生物在ADC领域研发实力的又一体现。Sacituzumab Tirumotecan作为公司核心管线产品，其临床进展备受市场关注。联合免疫检查点抑制剂的策略，旨在探索更有效的肿瘤治疗模式。
公司表示，将进一步分析详细数据，并与监管机构沟通后续事宜。这一里程碑事件有望推动该创新疗法早日惠及患者，并为公司带来新的增长动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.